Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 17083
Country/Region: Papua New Guinea
Year: 2017
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $2,486,306 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: TB/HIV (HVTB) $0
Laboratory Infrastructure (HLAB) $192,505
Strategic Information (HVSI) $259,259
Health Systems Strengthening (OHSS) $318,348
Testing: HIV Testing and Counseling (HVCT) $369,944
Sexual Prevention: Other Sexual Prevention (HVOP) $636,203
Treatment: Adult Treatment (HTXS) $710,047
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Number of people receiving post-GBV care 2018 50
GEND_GBV Number of people receiving post-GBV care 2018 200
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 3,438
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 4,820
HTS_TST Sum of Test Result disaggregates 2018 235
HTS_TST Sum of Test Result disaggregates 2018 299
HTS_TST_POS By Test Result: Positive 2018 235
HTS_TST_POS By Test Result: Positive 2018 299
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 1,770
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 415
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 100
KP_PREV By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 200
KP_PREV By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2018 315
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2018 2,800
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 820
TX_CURR Aggregated Age/Sex: 15+ Female 2018 4,115
TX_CURR Aggregated Age/Sex: 15+ Female 2018 401
TX_CURR Aggregated Age/Sex: 15+ Male 2018 3,120
TX_CURR Aggregated Age/Sex: 15+ Male 2018 305
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 7,235
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 706
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 7,235
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 706
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 7,235
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 706
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 271
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 154
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 207
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 116
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 478
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 270
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 478
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 270
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 3,337
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2018 354
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 3,003
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2018 318
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,705
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 181
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,298
TX_PVLS Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 137
TX_PVLS Numerator: Indication: Routine 2018 3,003
TX_PVLS Numerator: Indication: Routine 2018 318
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 1,893
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2018 202
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 1,444
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2018 152
TX_PVLS_den Denominator: Indication: Routine 2018 3,337
TX_PVLS_den Denominator: Indication: Routine 2018 354
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 245
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 139
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 185
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2018 104
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 430
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2018 243
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 478
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2018 270
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 271
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 154
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 207
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2018 116
Cross Cutting Budget Categories and Known Amounts Total: $2,893,824
Key Populations: MSM and TG $537,949
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Key Populations: Sex Workers $924,437
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Collection and use of strategic information on SWs and clients
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $1,131,438
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Condoms: Policy, Tools, and Services $100,000
Human Resources for Health $200,000